NEW YORK (GenomeWeb News) — Roche said today that revenue from its Molecular Diagnostics division declined during the first six months of the year, though overall Diagnostics revenue increased.
Also, Applied Science receipts increased on strong sales of its LightCycler 480 and Genome Sequencer 20 and GS FLX systems.
Separately today, Roche said that Roche Diagnostics CEO Severin Schwan will take over Franz Humer’s role as CEO of the entire Roche group so that Humer can focus on his role as chairman of Roche Holdings.
Humer, who will step down as CEO in March 2008, said the company decided to split the duties because of the “increasing complexity of the tasks involved” in the two positions. The company will name a successor for Schwan in its Diagnostics division at a later date.
Total receipts for the molecular diagnostics segment of Roche Diagnostics slipped 3 percent in the first half of 2007 compared with the same period one year ago, while overall Diagnostics revenue rose 7 percent year over year. Also, revenue from Diagnostics’ Applied Science segment rose 9 percent over the same period.
Diagnostics sales overall rang in at CHF 4.6 billion ($3.8 billion), while Molecular Diagnostics declined to CHF 574 million, and Applied Science brought in CHF 331 million in revenue.
Roche said the dip in Molecular Diagnostics was expected as it continues to see the effects of a drop-off in its industrial reagents sales. Also, sales in its blood-screening business “remained flat.”